MANNHEIM, Germany—Response to treatment is highly variable with the investigational PCSK9 inhibitor lerodalcibep (LIB Therapeutics), as well as with evolocumab (Repatha; Amgen), in patients who have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback